Experience:
No experience
Employment Type:
Full time
Posted:
10/2/2017
Job Category:
Research
See more jobs for students and recent grads who studied:
Research Investigator II - Web Id: 29274
Bristol-Myers Squibb Company | Newark, New Jersey
Tell Us More About Your Job Preferences
By telling us what you think of this job, we can help find jobs that match your interests. If you want to see more jobs like this, click on the smiley face. Or if this job isn't what you are looking for, click the frowny face. Learn More...

Follow This Company
Share

Job Description

Research Investigator II

Requires PhD in Computer Bioinformatics, Molecular Genetics, Biotechnology or related + 1year experience. Use experience with Illumina, PacBio, Nanopore, NextGen Sequencing technologies; GATK, Cufflinks, SAMtools, BAMtools, Cytoscape; ArrayStudio, Partek, Spotfire, Metabase, IPA; proficiency in machine learning, statistic modeling & data mining tools; knowledge of NCBI, Ensembl, ArrayExpress/GEO, SRA, TCGA, 1000 Genomes; ability to build custom software to leverage molecular genetics & work on next generation sequencing technologies & bioinformatics analysis. Bristol-Myers Squibb Company, Pennington, NJ. Full Time. 

 

Web Id: 29274. 


recblid gyxsuytsxl89fxl5vx1j6r6zasqudj

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical and nutritional products. The Company had two segments: Pharmaceuticals and Nutritionals. The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business. The Nutritionals segment consists of Mead Johnson Nutritionals (Mead Johnson), primarily an infant formula and children's nutritionals business. In June 2008, BMS acquired Kosan Biosciences, Inc., a developer of oncology products. In August 2008, the Company completed the divestiture of its ConvaTec business to Cidron Healthcare Limited, an affiliate of Nordic Capital Fund VII and Avista. In December 2008, BMS completed the sale of its brand business in Egypt to GlaxoSmithKline. In July 2009, the Company's branded generics business, which comprises a portfolio of 13 branded pharmaceuticals was acquired by GlaxoSmithKline plc.

This company profile was created by AfterCollege and is about Bristol-Myers Squibb Company. This page is not endorsed by or affiliated with Bristol-Myers Squibb Company. For questions regarding company profiles, please email: care@aftercollege.com.